Form 4: Roivant CEO Venker Sells Shares Under 10b5-1 Plan

Roivant Sciences Ltd.'s President and Immunovant CEO, Eric Venker, executed a series of stock option exercises and subsequent sales of common shares in mid-October 2025, totaling 851,383 shares, under a pre-arranged 10b5-1 trading plan.

Summary

• Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), engaged in transactions involving the company's common shares.
• The transactions occurred on October 15, 16, and 17, 2025.
• Venker exercised stock options to acquire a total of 851,383 common shares at an exercise price of $15.85 per share.
• Concurrently, he sold a total of 851,383 common shares at weighted average prices ranging from $16.93 to $17.06 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
• Following these transactions, Venker's direct beneficial ownership of common shares is 1,504,959.
• His beneficial ownership of stock options (right to buy) is now 0.

Sentiment

Score: 6

Explanation: The transactions represent a pre-planned exercise of options and sale of shares by an insider, indicating a scheduled liquidity event rather than a discretionary market timing decision. The insider realized a profit on the transactions, which is a neutral to slightly positive signal, but the act of selling itself can be viewed with slight caution.

Positives

• The execution of transactions under a Rule 10b5-1 trading plan demonstrates pre-planned, non-discretionary trading, which can mitigate concerns about insider trading.
• The sale prices ($16.93, $17.05, $17.06) are higher than the exercise price ($15.85), indicating a realized profit for the insider.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity exposure.

Future Outlook

NA

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
• These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by a high-ranking executive, even if pre-planned, could be interpreted by some shareholders as a reduction in management's direct equity alignment, though the 10b5-1 plan provides transparency.
• Management (Eric Venker): Realized a profit from exercising vested stock options and selling the underlying shares.

Key Dates

Recommendation

The filing reports a pre-planned exercise of stock options and subsequent sale of shares by a key executive under a Rule 10b5-1 trading plan. While insider selling can sometimes be a negative signal, the pre-scheduled nature of these transactions suggests a personal liquidity event rather than a reflection of new material information about the company's prospects. Therefore, it does not provide a strong basis for a change in investment recommendation, warranting a 'hold' position for existing investors.

Keywords

Roivant Sciences, ROIV, Eric Venker, Form 4, insider trading, stock options, 10b5-1 plan, share sale, CEO, Immunovant